Synageva BioPharma™ to Present at Upcoming Investor Conferences
Jefferies Global Healthcare Conference London 2012
LEXINGTON, Mass. -- November 07, 2012
Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare disorders,
today announced that Sanj K. Patel, President and Chief Executive Officer,
will present at the Jefferies 2012 Global Healthcare Conference in London,
England on Wednesday, November 14^th, 2012, at 10:00 a.m. GMT (5:00 a.m. EST).
In addition, the company will host one-on-one meetings at the Leerink Swann
Management Access Day on November 20, 2012 in Boston, MA.
The Jefferies conference presentation will be webcast live and may be accessed
from the “Webcasts & Presentations” section of the Investor Relations tab on
the home page of Synageva’s website at www.synageva.com.
About Synageva’s Lead Program
Sebelipase alfa is a recombinant form of the human Lysosomal Acid Lipase (LAL)
enzyme under development by Synageva as an enzyme replacement therapy for LAL
Deficiency, a lysosomal storage disorder (LSD). Synageva currently evaluates
sebelipase alfa in global clinical trials. Sebelipase alfa has been granted
orphan designations by the U.S. Food and Drug Administration (“FDA”), the
European Medicines Agency, and the Japanese Ministry of Health, Labour and
Welfare. Additionally, sebelipase alfa received “fast track” designation by
About LAL Deficiency
Lysosomal Acid Lipase Deficiency is a rare, autosomal recessive LSD that is
caused by a marked decrease in LAL enzyme activity. Late onset LAL Deficiency,
sometimes called Cholesteryl Ester Storage Disease (CESD), affects both
children and adults. In these patients, the buildup of fatty material in the
liver, spleen and blood vessel walls leads to complications resulting in
significant morbidity and mortality. Early onset LAL Deficiency, sometimes
called Wolman disease, affects infants and is characterized by severe
malabsorption, growth failure, and hepatic failure and is usually fatal within
the first year of life.
About Synageva BioPharma Corp.
Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products for
patients with life-threatening rare diseases and unmet medical need. Synageva
has several protein therapeutics in its pipeline. The company has assembled a
team with a proven record of bringing orphan therapies to patients.
Further information regarding Synageva BioPharma Corp. is available at
This news release contains “forward-looking statements” under the provisions
of the Private Securities Litigation Reform Act of 1995. Such statements can
be identified by introductory words such as “expects,” “plans,” “intends,”
“believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar
meaning, and by the fact that they do not relate strictly to historical or
current facts. Many factors may cause actual results to differ materially from
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, some of which are known, including those
identified under the heading “Risk Factors” in the Company’s Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on
November 6, 2012 and other filings Synageva periodically makes with the SEC,
and others of which are not. Synageva cannot be sure when or if it will be
permitted by regulatory agencies to undertake additional clinical trials or to
commence any particular phase of clinical trials or how quickly patient
enrollment in clinical trials will occur. In addition, early clinical results
are not necessary predictive of results that may be achieved from subsequent
clinical trials. Because of this, statements regarding the expected timing of
clinical trials or ultimate regulatory approval cannot be regarded as actual
predictions of when Synageva will obtain regulatory approval for any phase of
clinical trials or when it will obtain ultimate regulatory approval by a
particular regulatory agency or when any of its drug product candidates might
be commercialized. No forward-looking statement is a guarantee of future
results or events, and investors should avoid placing undue reliance on such
statements. Synageva undertakes no obligation to update any forward-looking
statements, whether as a result of new information, future events or
“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.
Synageva BioPharma Corp.
Matthew Osborne, 781-357-9947
Press spacebar to pause and continue. Press esc to stop.